Supplementary Figure S2 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

2026 Open access

Read full text
Authors: Bruna Pellini, Russell William Madison, Merrida A. Childress, Shoshana T. Miller, Ole V. Gjoerup, Jason Cheng, Richard S.P. Huang, Michael R. Krainock, Pratyush Gupta, Wei Zou, David S. Shames, Solomon Moshkevich
+6 more Marcus Ballinger, MC Liu, Amanda G. Young, Minu K. Srivastava, Geoffrey R. Oxnard, Mark A. Socinski
DOI: 10.1158/1078-0432.31085017
Cited by: 0

Abstract

Supplementary Figure S2: ctDNA decrease ≥ 50% or ≥ 90% at C4D1 on chemoIO identifies patients with poorer outcomes on IO maintenance

Fields of Study & Subjects

Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment

Publication details

Publication date
19 January 2026